• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Impact of COVID-19 on thrombus composition and response to thrombolysis: Insights from a monocentric cohort population of COVID-19 patients with acute ischemic stroke
CONCLUSIONS: These results show that COVID-19 does not impact NETs content or worsen fibrinolysis resistance of AIS thrombi, a therapeutic hurdle that could be overcome by DNase 1 even in the context of SARS-Cov-2 infection.PMID:35032088 | DOI:10.1111/jth.15646
Source: Thrombosis and Haemostasis - January 15, 2022 Category: Hematology Authors: Jean-Philippe Desilles Mialitiana Solo Nomenjanahary Arturo Consoli V éronique Ollivier Doroth ée Faille Marie-Charlotte Bourrienne Myl ène Hamdani S ébastien Dupont Lucas Di Meglio Simon Escalard Benjamin Maier Raphael Blanc Michel Piotin Bertrand La Source Type: research

Hypercoagulation and Antithrombotic Treatment in Coronavirus 2019: A New Challenge.
Abstract The novel coronavirus 2019 (COVID-19) is clinically characterized by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is responsible for a high number of patients needing mechanical ventilation or intensive care units treatment and for the elevated mortality risk. A link between COVID-19 and multiorgan failure may be dependent on the fact that most COVID-19 patients are complicated by pneumonia, which is known to be associated with early changes of clotting and platelet activation and artery dysfunction; these changes may implicate in thrombotic-related events such as myocardial infarct...
Source: Thrombosis and Haemostasis - April 28, 2020 Category: Hematology Authors: Violi F, Pastori D, Cangemi R, Pignatelli P, Loffredo L Tags: Thromb Haemost Source Type: research

Heparin-induced thrombocytopenia and thrombosis in a patient with Covid-19
Covid-19 has significant implications of hematologic systems, including lymphocytopenia, thrombocytopenia, ischemic or hemorrhagic stroke, pulmonary thromboembolism, and myocardial infarction [1,2]. Iwasaki et al. reported that the pathogen of Covid-19, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), can induce immune dysfunction, inflammation, and antibody-dependent enhancement by activating host cells via the Fc γIIa receptor in the same way as SARS-CoV-1 [3].
Source: Thrombosis Research - August 2, 2020 Category: Hematology Authors: Ching-Tai Huang, Shao-Yun Hsu, Ko-Wei Chang, Chung-Guei Huang, Cheng-Ta Yang, Ming-Huei Cheng Tags: Letter to the Editors-in-Chief Source Type: research

Coagulopathy and thromboembolic events in patients with SARS-CoV-2 infection: pathogenesis and management strategies
AbstractIn October 2019, a viral infectious disease appeared in the city of Wuhan in China. A new betacoronavirus, SARS-CoV-2, has been recognized as the responsible pathogen in this infection. Although coronavirus disease is principally expressed as a pulmonary infection, critical SARS-CoV-2 infection is frequently complicated with coagulopathy, and thromboembolic events are recognizable in several patients. Dehydration, acute inflammatory condition, protracted immobilization during disease, existence of multiple cardiovascular risk factors such as diabetes, obesity or hypertension, previous coronary artery disease, ische...
Source: Annals of Hematology - August 13, 2020 Category: Hematology Source Type: research

Pulmonary venous thrombosis in a patient with COVID-19 infection
ConclusionsThrombotic outcomes in the setting of severe COVID 19 pneumonia may include macrovascular venous thromboembolism, microvascular pulmonary vascular thrombosis and arterial thromboembolism. Pulmonary vein, herein described, provides further mechanistic pathway for potential arterial embolic phenomenon.
Source: Journal of Thrombosis and Thrombolysis - January 30, 2021 Category: Hematology Source Type: research

Hereditary thrombotic thrombocytopenic purpura and COVID-19: Impacts of vaccination and infection in this rare disease
DISCUSSION: The risk of an acute episode triggered by COVID-19 seems higher than following vaccination in hTTP patients, who can be safely vaccinated against SARS-CoV-2.PMID:36284639 | PMC:PMC9585384 | DOI:10.1002/rth2.12814
Source: Thrombosis and Haemostasis - October 26, 2022 Category: Hematology Authors: Erika Tarasco Anne Sophie von Krogh Radomira Hrdlickova Thomas R Braschler Teresa Iwaniec Paul N Kn öbl Eriko Hamada Oleg Pikovsky Stefan Farese Odit Gutwein Petr Kessler Nina H Schultz Charis von Auer Jerzy Windyga Kenneth Friedman Ingrid Hrachovinova J Source Type: research